Lab Study: Engineered Immune Progenitor Cells Target Leukemia and Solid Tumors in Mice

Preclinical research from USC shows that CAR-equipped granulocyte-monocyte progenitors can suppress cancer in mouse models — but human trials have not begun and the results have not been replicated in humans.

Researchers at the University of Southern California’s Keck School of Medicine have engineered granulocyte-monocyte progenitor (GMP) cells to express chimeric antigen receptors (CARs) and demonstrated anti-tumor activity in mouse models of CD19-positive leukemia and HER2-positive solid tumors, according to a study published in Cell.

This is preclinical research conducted in rodents. No human clinical trial has been registered, initiated, or planned based on these findings.

What the Researchers Did

GMP cells are bone marrow progenitors that give rise to multiple myeloid effector populations, including macrophages, dendritic cells, and granulocytes. The USC team used gene-editing techniques to introduce CAR constructs into GMP cells — creating what they term CAR-GMPs — and evaluated their activity in transplanted mouse tumor models.

Unlike CAR-T cells, which target tumors through T-cell cytotoxicity, CAR-GMP cells act via phagocytosis and innate immune signaling. The research group proposed that myeloid-lineage effectors may be better positioned to penetrate immunosuppressive tumor microenvironments that resist T-cell infiltration — a hypothesis supported by the mouse model results but untested in humans.

In CD19-positive leukemia models, anti-CD19 CAR-GMP cells significantly reduced tumor burden compared with controls. In HER2-positive solid tumor models, anti-HER2 CAR-GMPs showed measurable anti-tumor activity. The team also tested the approach in a mouse model of chronic granulomatous disease, a primary immunodeficiency caused by defective phagocyte function, and observed restoration of some phagocytic activity.

What the Study Does Not Establish

Mouse tumor models are valuable for hypothesis generation but are unreliable predictors of human response. Key unknowns include durability of CAR-GMP activity in vivo, cytokine release risk, manufacturing scalability for clinical-grade production, and whether the anti-tumor signal in rodents translates to human cancer biology.

Mouse models frequently fail to predict human responses — including in oncology, where numerous promising preclinical programs have not replicated clinically. The distance between these results and a clinical proof of concept is substantial.

USC Keck School of Medicine. CAR-GMP progenitor cell therapy. Cell. 2026. DOI: 10.1016/j.cell.2026.05.043. PMID: 42320470.

Trace · every claim, sourced

Reported and written by Dr. Lena Fischer, Research & Preprints Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

Researchers at USC engineered granulocyte-monocyte progenitor cells to express chimeric antigen receptors and demonstrated tumor-suppressive activity in mouse models of CD19-positive leukemia and HER2-positive solid tumors.

journal_article PMID 42320470 — CAR-GMP progenitor cell therapy, Cell 2026 PMID:42320470

This research is preclinical (mouse models only); no human clinical trial of CAR-GMP cells has been registered or initiated.

journal_article CAR-equipped granulocyte-monocyte progenitor cells suppress leukemia and solid tumors in mice — Cell 2026 10.1016/j.cell.2026.05.043

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.